New combo therapy targets liver metastases in rare eye cancer
NCT ID NCT06626516
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study tests a drug called tebentafusp combined with treatments directed at the liver (like embolization or chemo-embolization) for people with a rare eye cancer (uveal melanoma) that has spread to the liver. About 109 adults with a specific immune type (HLA-A*0201) will participate. The goal is to see if the combination is safe and helps control the cancer longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo tame a rare eye cancer that has spread?
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer